Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 5/20 | 0.41 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18683503 | 0.88 | CTSS (0.42) | CTSSCTSKPTPN1ATM | |
| SCHEMBL8901382 | 0.86 | CTSS (0.45) | CTSSCTSKPTPN1PPARAPPARG | |
| SCHEMBL8546353 | 0.85 | CTSS (0.41) | CTSSCTSKPTPN1PPARAPPARG | |
| SCHEMBL4178016 | 0.83 | HTT (0.44) | — | |
| SCHEMBL23886587 | 0.82 | CTSS (0.49) | CTSSCTSKPTPN1PPARAPPARG | |
| SCHEMBL30370355 | 0.82 | CTSS (0.49) | CTSSCTSKPTPN1PPARAPPARG | |
| SCHEMBL16334202 | 0.82 | CTSS (0.49) | CTSSCTSKPTPN1PPARAPPARG | |
| SCHEMBL30370648 | 0.82 | CTSS (0.49) | CTSSCTSKPTPN1PPARAPPARG | |
| SCHEMBL29571369 | 0.82 | CTSS (0.49) | CTSSCTSKPTPN1PPARAPPARG | |
| SCHEMBL8511514 | 0.82 | CTSS (0.49) | CTSSCTSKPTPN1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20050209177-A9 | Combined therapeutical treatment of hyperproliferative diseases | TOCQUE BRUNO | 2005-09-22 | — | — | US | disclosed |
| US-20040127437-A1 | Combined therapeutical treatment of hyperproliferative diseases | TOCQUE BRUNO (FR) | 2004-07-01 | — | — | US | disclosed |
| US-20010021395-A1 | Method for destroying hyperproliferative cells by combined p53 and taxoid treatment | TOCQUE BRUNO (FR) | 2001-09-13 | — | — | US | disclosed |
| US-6262032-B1 | WHEREIN THE ADENOVIRAL VECTOR AND THE TAXOID COMPOUND ARE BROUGHT INTO CONTACT WITH THE CELL SIMULTANEOUSLY. | AVENTIS PHARMA S.A. (FR) | 2001-07-17 | — | — | US | disclosed |
| US-5686622-A | Thiazolidine derivatives, their preparation and the medicaments containing the same | RHONE-POULENC RORER S.A. (FR) | 1997-11-11 | — | — | US | disclosed |
| US-5670536-A | Pharmaceutical composition based on taxoids | RHONE-POULENC RORER S.A. (FR) | 1997-09-23 | — | — | US | disclosed |
| US-5606068-A | Acid anhydrides, their preparation and their use | RHONE-POULENC RORER S.A. (FR) | 1997-02-25 | — | — | US | disclosed |
| US-5476954-A | Condensing hydroxyl protected taxane derivative with oxazolidine derivative, decyclizing in acid medium, reacting butoxycarbonyl or benzoyl radical with amine, deprotecting, isolating, purifying product | RHONE-POULENC RORER S.A. (FR) | 1995-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | ABCC1, AZI2, TPD52L2 | CTSS 4449/4885CTSK 4401/4885PTPN1 1026/4885 |
| US-20010021395-A1 | Method for destroying hyperproliferative cells by combined p53 and taxoid treatment | TP53, HRAS, MYC | CTSS 2004/4885CTSK 1348/4885PTPN1 1821/4885 |
| US-20050209177-A9 | Combined therapeutical treatment of hyperproliferative diseases | HRAS, MYC, TP53 | CTSS 3468/4885CTSK 3043/4885PTPN1 1869/4885 |
| US-20040127437-A1 | Combined therapeutical treatment of hyperproliferative diseases | HRAS, MYC, TP53 | CTSS 3468/4885CTSK 3043/4885PTPN1 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.